Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. - Wikidata - thesis-toulmin - TriplyDB

Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.

Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.

http://www.wikidata.org/entity/Q53108240

about

Monitoring anticoagulant therapy with new oral agents Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation.A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?Dabigatran for the prevention and treatment of thromboembolic disorders.Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?Measurement and reversal of the direct oral anticoagulants.Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG®), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT).Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation.Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure.Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register.Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations.Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation.Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods.Development and Validation of RP-UPLC Method for the Determination of Process and Degradant Impurities Present in Dabigatran Etexilate Mesylate Capsules Using High Strength Silica-T3 Sorbent Column Validation of an LC–MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma

P2860

Q26771728-B9FA0ADC-C253-4DDE-B578-0C09959C5036 Q28081918-DB48D924-D2A3-41EF-829A-27D10CE5D5E8 Q34206252-D3664EF2-CF92-4915-938F-7ACDA14FDFE5 Q34207558-2E07F1C6-A9F9-458E-BE0A-733D4F59D229 Q34571082-C3DA22FF-6F13-47C7-B4CE-718C5ADAA506 Q34571099-CEB0AA1C-B73F-43FA-8E97-FFAE327A693E Q35154142-080E8F9D-7529-4AA6-8FA3-0FB60FDAC890 Q35674404-1FEB25AC-9E7C-4EA6-B288-E2E7622914AA Q36013432-DA90C6F3-F32D-490C-9F12-FF477E8203A6 Q38199371-1ECD8265-BE23-45FF-9150-6903A6CD5DB2 Q38252945-A90B9E11-E1A8-42A4-8C63-5C6E819088EE Q38406325-19F5C5F3-F1D4-417F-AAB5-FC1D8E7CEDF1 Q38589753-5E9470C1-FF4D-491C-A455-58C7605F52BE Q38620930-1942D066-8567-4F62-8DEE-CDB5BD5F4239 Q38895665-A548D4BA-04F5-4A0F-9D14-D9A33F395B74 Q38953781-345A488C-9F12-40EB-9F8A-209A13631263 Q38956699-4635270C-51D7-4E13-84F4-6E7A87E1D4B9 Q40744632-2AD53233-A502-4640-B6F3-D5839C61FFC1 Q45879084-447A6D2E-5FA4-4563-9882-3B301D9C273C Q47204779-BF1BC2B3-2924-4683-8F78-104B648CB99B Q47210396-17108C87-8473-438E-B8DE-3C070F593EFF Q47633775-78DA8A38-C9E1-4EE1-BD25-2D88179CA997 Q48285817-5BA45EF3-88AC-4E42-BA8B-7AA05A432433 Q48829029-DA9B6F62-5D39-4EF1-8D39-1C43D201F0E1 Q53342787-A2287208-F304-4CB9-B188-4E649B33AF13 Q53468814-D8B574E7-A75B-4C96-BAC3-FF56E7390C29 Q53484741-6CD9826B-80F6-4C84-8063-4F1C8AA31305 Q53502627-A429B997-21DD-458C-BB12-B0A8239567DB Q53595977-59255AC9-4BCA-47BA-9B2C-8AB17CB46CCA Q58180540-1C4FB574-3BD8-4160-9970-DD421FDA3815 Q58420626-3184275F-60CF-4CE4-95A2-AB2B26987A40

P2860

Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.

http://www.wikidata.org/entity/Q53108240

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Evaluation of coagulation assa ...... tran concentrations in plasma.

@en

Evaluation of coagulation assa ...... tran concentrations in plasma.

@nl

type

label

Evaluation of coagulation assa ...... tran concentrations in plasma.

@en

Evaluation of coagulation assa ...... tran concentrations in plasma.

@nl

prefLabel

Evaluation of coagulation assa ...... tran concentrations in plasma.

@en

Evaluation of coagulation assa ...... tran concentrations in plasma.

@nl

P1433

Q53108240-48F053AF-41AC-4D10-A0C0-CE8525876C80

P1476

Q53108240-5C3D3CA0-3B30-4F06-880F-AD0C934F6DD1

P2093

Q53108240-2138C637-BD4B-490B-99E0-A69047F435F9

Q53108240-245A4882-403A-49D1-BD5B-C28ECB5E4EA5

Q53108240-3210D307-8B5A-4DD6-AC7D-A77693836F5E

Q53108240-35C9CE9B-CC53-4B2E-BFC0-D798BD6311E3

Q53108240-3FF4F9A2-8189-4681-8D06-8AC930721D7A

Q53108240-4CCF4B0E-CDB6-4D63-9932-71582BB25FDB

Q53108240-601251A7-E8E8-40F0-AD96-518E18AB8019

Q53108240-A460ADBA-D0AD-415E-A7DC-912E09C8660F

Q53108240-D98CA53A-705C-4D04-A19A-D74275E0D711

Q53108240-ECC20D42-47D1-45A1-9996-D24072179462

P2860

Q53108240-06378D04-350A-449D-AEE3-48FF6DD76DFB

Q53108240-36166547-B506-4AFD-A6C0-294526139DFF

Q53108240-4B519F10-A1C6-4E25-A6B0-FE5DFB913FCA

Q53108240-69E652E2-D2C6-4F5D-840C-1418950C29A3

Q53108240-A7905295-3EB6-4F28-9E0D-6C114974C87F

Q53108240-D18C1792-27AD-4A44-B2E2-56496EB60F7A

Q53108240-D6C06734-AEEA-4ABD-AA77-739D1C0C3947

Q53108240-E652B17A-41E9-441D-BB4E-9D5D892B7F0E

Q53108240-EE3BBF7D-73E5-4DA5-B494-41601DC59169

P2888

Q53108240-FBDD42DA-3518-4F0F-BFDA-A28EAE7DE4E3

P304

Q53108240-0C49C8FC-3CB2-46E9-AD05-C11E4F72B20B

P31

Q53108240-FAE9ADF6-DFCC-484B-97FD-CDADDC15698E

P356

Q53108240-4010FC37-D072-4087-A9EB-79C0796B5B55

P433

Q53108240-23021E04-48E6-46BF-B0A6-D7A6878CFFF6

P478

Q53108240-93287E30-029E-498C-BF71-71C71627A085

P50

Q53108240-89C80621-5F1D-4B47-B3B3-12684DA2DD17

Q53108240-B0A3F3E3-AB65-4988-B212-C2F8FB7B2A83

P577

Q53108240-5841ACAE-E3F7-4B85-8E6F-6BB6A7756FED

P698

Q53108240-9BB01C8D-9993-4EEE-9516-17267CBE0BCB

P356

S00228-013-1550-4

P1433

European Journal of Clinical Pharmacology

P1476

Evaluation of coagulation assa ...... tran concentrations in plasma.

@en

P2093

Anton Pohanka

http://www.w3.org/2001/XMLSchema#string

Elisabet Eriksson Boija

http://www.w3.org/2001/XMLSchema#string

Eva-Marie Norberg

http://www.w3.org/2001/XMLSchema#string

Jaak Eintrei

http://www.w3.org/2001/XMLSchema#string

Jovan P Antovic

http://www.w3.org/2001/XMLSchema#string

Lisbeth Söderblom

http://www.w3.org/2001/XMLSchema#string

Liselotte Onelöv

http://www.w3.org/2001/XMLSchema#string

Mika Skeppholm

http://www.w3.org/2001/XMLSchema#string

Rickard E Malmström

http://www.w3.org/2001/XMLSchema#string

Yuko Rönquist-Nii

http://www.w3.org/2001/XMLSchema#string

P2860

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.

The laboratory and the new oral anticoagulants.

Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

P2888

s00228-013-1550-4

P304

1875-1881

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-013-1550-4

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23784008

http://www.w3.org/2001/XMLSchema#string